Literature DB >> 19057446

Incidence and risk factors of upper gastrointestinal bleeding in mechanically ventilated children.

Jitladda Deerojanawong1, Danayawan Peongsujarit, Boosba Vivatvakin, Nuanchan Prapphal.   

Abstract

OBJECTIVE: To identify the incidence and factors related to upper gastrointestinal (UGI) bleeding in children requiring mechanical ventilation for longer than 48 hrs.
DESIGN: Prospective analytic study.
SETTING: Ten-bed-pediatric intensive care unit of a tertiary care University Hospital. PATIENTS: A total of 110 patients requiring mechanical ventilation for longer than 48 hrs from January 1, 2005 to December 31, 2005. MEASUREMENTS AND
RESULTS: UGI bleeding was defined by evidence of blood in nasogastric aspirates, hematemesis, or melena within 5 days of pediatric intensive care unit admission. We prospectively collected data on patient demographics, admission diagnosis, operative status, and pediatric risk of mortality score. UGI bleeding and the potential risk factors including organ failure, coagulopathy, maximum ventilator setting, enteral feeding, stress ulcer prophylaxis as well as sedation were daily monitored. Of the 110 patients who required mechanical ventilation for >48 hrs, the incidence of UGI bleeding was 51.8%, in which 3.6% of the cases presented with clinically significant bleeding (shock, requiring blood transfusion and/or surgery). Significant risk factors were thrombocytopenia, prolonged partial thromboplastin time, organ failure, high pressure ventilator setting >/=25 cm H2O, and pediatric risk of mortality score >/= 10 using univariate analysis. However, the independent factors of UGI bleeding in the multivariate analysis were organ failure (relative risk = 2.85, 95% confidence interval 1.18-6.92) and high pressure ventilator setting >/=25 cm H2O (relative risk = 3.73, 95% confidence interval 1.59-8.72).
CONCLUSION: The incidence of UGI bleeding is high in children requiring mechanical ventilation. Organ failure and high pressure ventilator setting are significant risk factors for UGI bleeding.

Entities:  

Mesh:

Year:  2009        PMID: 19057446     DOI: 10.1097/PCC.0b013e3181936a37

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  8 in total

1.  Impact of Acid Suppression Therapy on Iron Supplementation in the Pediatric Intensive Care Unit.

Authors:  Emily Hailstone; Sheryl Falkos; Rosa Vidal; K Ashley Jones; Philippe R Gaillard; Shirley Fan; Allison M Chung
Journal:  J Pediatr Pharmacol Ther       Date:  2021-05-19

2.  Supportive care of a critically ill child.

Authors:  Sunil Saharan; Rakesh Lodha; Sushil K Kabra
Journal:  Indian J Pediatr       Date:  2010-12-31       Impact factor: 1.967

3.  Upper GI bleeding among neonates admitted to Mulago Hospital, Kampala, Uganda: a prospective cohort study.

Authors:  O M Ombeva; G Ndeezi; J Mugalu
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

Review 4.  Fasting for haemostasis in children with gastrointestinal bleeding.

Authors:  Shuang-Hong Luo; Qin Guo; Guan J Liu; Chaomin Wan
Journal:  Cochrane Database Syst Rev       Date:  2016-05-19

5.  Management by the intensivist of gastrointestinal bleeding in adults and children.

Authors:  David Osman; Michel Djibré; Daniel Da Silva; Cyril Goulenok
Journal:  Ann Intensive Care       Date:  2012-11-09       Impact factor: 6.925

6.  Pediatric intensive care stress ulcer prevention (PIC-UP): a protocol for a pilot randomized trial.

Authors:  Mark Duffett; Karen Choong; Jennifer Foster; Elaine Gilfoyle; Jacques Lacroix; Nikhil Pai; Lehana Thabane; Deborah J Cook
Journal:  Pilot Feasibility Stud       Date:  2017-05-19

7.  Ibuprofen, a Potential Cause of Acute Hemorrhagic Gastritis in Children - A Case Report.

Authors:  Maria Oana Mărginean; Lorena Elena Meliț; Simona Mocanu; Vlăduț Săsăran
Journal:  J Crit Care Med (Targu Mures)       Date:  2018-10-01

8.  Stress ulcer prophylaxis versus placebo-a blinded randomized control trial to evaluate the safety of two strategies in critically ill infants with congenital heart disease (SUPPRESS-CHD).

Authors:  Kimberly I Mills; Ben D Albert; Lori J Bechard; Christopher P Duggan; Aditya Kaza; Seth Rakoff-Nahoum; Hera Vlamakis; Lynn A Sleeper; Jane W Newburger; Gregory P Priebe; Nilesh M Mehta
Journal:  Trials       Date:  2020-06-29       Impact factor: 2.728

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.